Polar Capital Holdings’s Jazz Pharmaceuticals JAZZ Stock Holding History

Polar Capital Holdings’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-100,000	Closed	-$15.6K	–	457
2022 Q1	$15.6K	Sell	100,000 -250,000	-71%	-$36.3M	0.07%	190
2021 Q4	$44.6K	Buy	350,000 +75,000	+27%	+$9.86M	0.17%	108
2021 Q3	$35.8K	Buy	275,000 +125,000	+83%	+$18.9M	0.15%	127
2021 Q2	$26.6K	Buy	150,000 +25,000	+20%	+$4.33M	0.12%	142
2021 Q1	$20.5M	Buy	125,000 +50,000	+67%	+$8.23M	0.13%	153
2020 Q4	$12.4M	Buy	+75,000	New	+$11.2M	0.08%	190

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Polar Capital Holdings's JAZZ Position: Q2 2022 in Review

Polar Capital Holdings sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2022, closing a stake of 100,000 shares — an estimated $15.6K sold.

Polar Capital Holdings first reported a position in JAZZ in Q4 2020 and held it in 6 quarters. The position peaked at $20.5M in Q1 2021. 468 funds tracked by Wall St. Rank hold JAZZ as of Q2 2022.

Polar Capital Holdings reported no remaining Jazz Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Polar Capital Holdings sold 100,000 Jazz Pharmaceuticals shares in Q2 2022, an estimated $15.6K.
Polar Capital Holdings first reported a position in Jazz Pharmaceuticals in Q4 2020 and held it in 6 quarters.
Polar Capital Holdings's Jazz Pharmaceuticals position peaked at $20.5M in Q1 2021.
468 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2022.

Based on Polar Capital Holdings's 13F filing for Q2 2022, filed 15 Aug 2022.